Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
CVS owns all three links of the US drug and coverage chain: Aetna insurance (26M medical members), Caremark (one of three PBMs that process about 80% of US prescription claims) and roughly 9,000 retail pharmacies. The bundle is real and hard to copy, but each piece faces a sharper rival on its own, and PBM reform, already law in Medicare Part D, targets the most profitable link.
CVS is the only company that runs a national insurer, a top-three PBM and the largest US pharmacy chain together. The moat is the chain, not any one link:
- Caremark: One of the Big Three PBMs: Caremark processed about 1.9 billion 30-day-equivalent prescription claims in 2025. With Express Scripts and Optum Rx it handles about 80% of US claims, according to Drug Channels. Q2 2026 Health Services revenue was $51.8B, up 11.5%. Scale lets Caremark negotiate rebates and pharmacy rates that small PBMs cannot.
- Aetna: Repaired, Not Restored: Aetna's medical benefit ratio fell to 87.4% in Q2 2026 from 89.9% a year earlier, and Health Care Benefits adjusted operating income rose to $2.43B from $1.31B. The repair came from pricing and exiting unprofitable markets, which is why Medicare Advantage membership slipped to 4.20M. For 2027 star ratings, more than 69% of Aetna MA members are in 4+ star plans, down from about 81%.
- Retail Pharmacy: The Physical Front Door: About 9,000 CVS Pharmacy locations sit within a short drive of most Americans and fill prescriptions for Caremark and Aetna members as well as rivals' members. Pharmacy and Consumer Wellness revenue was $33.8B in Q2 2026, up 0.7%, with adjusted operating income up 10.2% as store closures and rival bankruptcies concentrated volume.
Moat Verdict
CVS's one strong pillar is the insurer-PBM-pharmacy bundle; every other pillar is a real advantage that Cigna or UnitedHealth matches. AI can automate pharmacy and claims operations, which helps a cost-focused integrated operator, but the main risk to the moat is PBM regulation, not AI.
65.0 resilient · 65.0 vulnerable · 80/20 = 65.0 · = 65
Open a moat to read its note.
Employers, pharmacists and providers learn Caremark and Aetna portals and benefit tools, but Express Scripts, Optum Rx and other insurers offer equivalent tools.
Formulary design, rebate contracting and actuarial pricing are sophisticated, but Express Scripts and Optum Rx run the same kinds of logic.
CVS's data advantage is private pharmacy and claims data, rated under proprietaryData; it never rested on public data.
Pharmacists, PBM contracting specialists and actuaries are hired from the same pool as Cigna, UnitedHealth and Walgreens.
Aetna insurance, Caremark (one of three PBMs that process about 80% of US prescription claims) and about 9,000 retail pharmacies make the only US bundle of a national insurer, a top-three PBM and the largest pharmacy chain. No figure on file shows how many Aetna members use Caremark or CVS stores, or that clients cannot buy the pieces apart, so it rates intact under M9; Caremark's claim volume is credited under scaleEconomics.
Prescription and claims data across Caremark, Aetna and the pharmacies is large, but it is the same class of data Express Scripts and Optum Rx hold (M5).
State insurance licences, CMS contracts and pharmacy licences bar entrants, but UnitedHealth, Cigna and Elevance hold the same approvals (M4). Aetna's star ratings are a yearly payment input, not a lock: more than 69% of MA members are in 4+ star plans for 2027, down from about 81%.
Caremark's pharmacy network and Aetna's provider network matter to employers, but Aetna's roughly 26M medical members are about half UnitedHealth's base and it holds no in-state Blue Cross position like Elevance's, so providers do not need Aetna the way they need the dominant local plan. Pharmacies and providers contract with every large PBM and insurer.
Caremark runs pharmacy benefits inside employer and health-plan operations, but large clients re-bid PBMs every three to five years and no retention figure is on file.
CVS pharmacies and Caremark hold prescription histories that pharmacists and prescribers check, but every PBM and pharmacy chain holds the same record for its own members.
Caremark's 1.9 billion claims in 2025 and about 9,000 stores give buying and rebate leverage, but Express Scripts processed more claims (2.22 billion, per Drug Channels) and the scale has not protected retail margins.
Pharmacy choice runs on location and insurance network, not a brand premium; not credited separately.
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
CVS owns all three links of the US drug and coverage chain: Aetna insurance (26M medical members), Caremark (one of three PBMs that process about 80% of US prescription claims) and roughly 9,000 retail pharmacies. The bundle is real and hard to copy, but each piece faces a sharper rival on its own, and PBM reform, already law in Medicare Part D, targets the most profitable link.
Growth Score
Q2 2026 (reported August 5, 2026) revenue was $106.1B, up 7.3%, with adjusted EPS of $2.58 versus $1.81. Health Services (Caremark) revenue grew 11.5% to $51.8B. Health Care Benefits (Aetna) revenue grew 3.5% to $37.5B while the medical benefit ratio improved to 87.4% from 89.9% and adjusted operating income nearly doubled. Pharmacy and Consumer Wellness revenue was flat at $33.8B. Management raised FY2026 adjusted EPS guidance to $7.90-$8.10 from $7.30-$7.50 and operating cash flow guidance to at least $11.5B, against FY2025 adjusted EPS of $6.75 on $402.1B of revenue.
Valuation Score
At $86.16 (October 9, 2026 close) CVS sits about 53% of the way from the $65 bear to the $105 base, at about 10.8× the $7.90-$8.10 FY2026 adjusted EPS guide. The base assumes about 12× roughly $8.75 of 2027 EPS, an inferred figure (the guide midpoint plus about 9% from continued Aetna margin repair), not company guidance; 12× sits below Elevance's roughly 15× because a bigger share of CVS earnings is exposed to PBM reform. It is below the Street mean of about $116 because commercial PBM reform and Aetna's lower 2027 star ratings cap the multiple. The score is the formula at $86.16 on a $65 / $105 / $135 ladder.
Insurer, PBM and Pharmacy in One
CVS is the only company that runs a national insurer, a top-three PBM and the largest US pharmacy chain together. The moat is the chain, not any one link:
- Caremark: One of the Big Three PBMs: Caremark processed about 1.9 billion 30-day-equivalent prescription claims in 2025. With Express Scripts and Optum Rx it handles about 80% of US claims, according to Drug Channels. Q2 2026 Health Services revenue was $51.8B, up 11.5%. Scale lets Caremark negotiate rebates and pharmacy rates that small PBMs cannot.
- Aetna: Repaired, Not Restored: Aetna's medical benefit ratio fell to 87.4% in Q2 2026 from 89.9% a year earlier, and Health Care Benefits adjusted operating income rose to $2.43B from $1.31B. The repair came from pricing and exiting unprofitable markets, which is why Medicare Advantage membership slipped to 4.20M. For 2027 star ratings, more than 69% of Aetna MA members are in 4+ star plans, down from about 81%.
- Retail Pharmacy: The Physical Front Door: About 9,000 CVS Pharmacy locations sit within a short drive of most Americans and fill prescriptions for Caremark and Aetna members as well as rivals' members. Pharmacy and Consumer Wellness revenue was $33.8B in Q2 2026, up 0.7%, with adjusted operating income up 10.2% as store closures and rival bankruptcies concentrated volume.
Moat Verdict
CVS's one strong pillar is the insurer-PBM-pharmacy bundle; every other pillar is a real advantage that Cigna or UnitedHealth matches. AI can automate pharmacy and claims operations, which helps a cost-focused integrated operator, but the main risk to the moat is PBM regulation, not AI.
65.0 resilient · 65.0 vulnerable · 80/20 = 65.0 · = 65
Open a moat to read its note.
Employers, pharmacists and providers learn Caremark and Aetna portals and benefit tools, but Express Scripts, Optum Rx and other insurers offer equivalent tools.
Formulary design, rebate contracting and actuarial pricing are sophisticated, but Express Scripts and Optum Rx run the same kinds of logic.
CVS's data advantage is private pharmacy and claims data, rated under proprietaryData; it never rested on public data.
Pharmacists, PBM contracting specialists and actuaries are hired from the same pool as Cigna, UnitedHealth and Walgreens.
Aetna insurance, Caremark (one of three PBMs that process about 80% of US prescription claims) and about 9,000 retail pharmacies make the only US bundle of a national insurer, a top-three PBM and the largest pharmacy chain. No figure on file shows how many Aetna members use Caremark or CVS stores, or that clients cannot buy the pieces apart, so it rates intact under M9; Caremark's claim volume is credited under scaleEconomics.
Prescription and claims data across Caremark, Aetna and the pharmacies is large, but it is the same class of data Express Scripts and Optum Rx hold (M5).
State insurance licences, CMS contracts and pharmacy licences bar entrants, but UnitedHealth, Cigna and Elevance hold the same approvals (M4). Aetna's star ratings are a yearly payment input, not a lock: more than 69% of MA members are in 4+ star plans for 2027, down from about 81%.
Caremark's pharmacy network and Aetna's provider network matter to employers, but Aetna's roughly 26M medical members are about half UnitedHealth's base and it holds no in-state Blue Cross position like Elevance's, so providers do not need Aetna the way they need the dominant local plan. Pharmacies and providers contract with every large PBM and insurer.
Caremark runs pharmacy benefits inside employer and health-plan operations, but large clients re-bid PBMs every three to five years and no retention figure is on file.
CVS pharmacies and Caremark hold prescription histories that pharmacists and prescribers check, but every PBM and pharmacy chain holds the same record for its own members.
Caremark's 1.9 billion claims in 2025 and about 9,000 stores give buying and rebate leverage, but Express Scripts processed more claims (2.22 billion, per Drug Channels) and the scale has not protected retail margins.
Pharmacy choice runs on location and insurance network, not a brand premium; not credited separately.
Growth Analysis
Growth Drivers
Key Risk
Part D delinking is already law (signed February 3, 2026) and is in the base. The pending risk is that the same flat-fee, full pass-through model is extended to commercial and employer plans, or that states ban PBM ownership of pharmacies, before 2028, cutting Caremark's spread and rebate income across the book that carries about half of CVS revenue.
Score Derivation
61.3 base + 4 margin − 5 risk = 60
Base about 61 (3-6% CAGR, midpoint 4.5%) + 0 trajectory (Caremark, Aetna and retail all held stable: Caremark revenue +11.5% in Q2 2026 but claims only +0.9% and no prior-period segment rate on file) + 4 expanding margin (Aetna benefit ratio down 250bps YoY; adjusted operating income up in all three segments) - 5 moderate risk (commercial PBM reform still pending; Part D delinking is already in the base) = about 60.
Price Scenarios (12–24 Months)
Price vs Targets
Dashed lines mark the 12–24 month bear, base and bull targets. Daily closes.
Valuation Multiples
| P/E (FY2026 adj. guide) | ~10.8× |
| Price / Sales | ~0.27× |
| Dividend yield | ~3.1% |
CVS trades at a low-teens-or-below multiple because the market prices each segment's worst case at once: PBM reform for Caremark, Medicare Advantage policy for Aetna and secular decline for retail. Earnings are recovering fast from the 2024-2025 Aetna trough, which is what the base pays for.
Approximate figures as of October 2026.
Where We Are vs Targets
Loading live price…
PBM reform cuts Caremark's economics, Aetna's lower 2027 star ratings trim 2028 bonuses, and EPS stalls near $8 at an 8× multiple.
- Congress or the states extend Part D-style delinking and full pass-through to commercial plans, or ban PBM ownership of pharmacies, cutting Health Services adjusted operating income
- Aetna's MA medical benefit ratio climbs back toward 89% as cost trend outruns 2027 pricing
- Retail pharmacy reimbursement keeps falling faster than front-store and volume gains, pushing Pharmacy and Consumer Wellness income lower
Aetna's margin repair continues into 2027, Caremark absorbs reform with contract changes, and the stock re-rates to about 12× roughly $8.75 of 2027 EPS.
- FY2026 adjusted EPS lands in or above the $7.90-$8.10 range and 2027 estimates rise on Aetna margin
- Caremark renews its large clients through 2027 with pass-through pricing models that hold segment income
- Aetna keeps more than 60% of MA members in 4+ star plans in the 2028 ratings, limiting the bonus loss
The integrated model proves its worth: Aetna margins return to target, Caremark grows through reform, and the market pays about 14× for EPS near $9.50.
- Aetna's medical benefit ratio settles in the mid-80s and Health Care Benefits earns its long-term margin target
- PBM reform lands as transparency rules that Caremark already meets, removing the overhang
- Retail consolidation after rival closures lifts pharmacy volume and margin